|
|
|
This is the preliminary program for the 2009 Joint Statistical
Meetings in Washington, DC.
|
|
|
The views expressed here are those of the individual authors and not necessarily those of the ASA or its board, officers, or staff. Back to main JSM 2009 Program page |
= Applied Session,
= Theme Session,
= Presenter
1
|
Sun, 8/2/09, 2:00 PM - 3:50 PM | CC-202A |
| The Statistical Issues Surrounding Progression-Free Survival in Oncology Drug Development - Invited - Papers | ||
|
Biopharmaceutical Section, Biometrics Section |
||
| Organizer(s): William D. Bushnell, GlaxoSmithKline, Rajeshwari Sridhara, FDA | ||
| Chair(s): Rajeshwari Sridhara, FDA | ||
| 2:05 PM |
On Analysis of Progression-Free-Survival —  Cong Chen, Merck Research Laboratories
|
|
| 2:25 PM |
Interval Censoring in Time-to-Progression Data — Zhenming Shun, sanofi-aventis
|
|
| 2:45 PM |
Central Review of Progression-Free Survival in Phase 3 Oncology Trials — Ohad Amit, GlaxoSmithKline; Frank Mannino, GlaxoSmithKline
|
|
| 3:05 PM |
Use of Blinded Independent Review for Auditing Purposes — Lori Dodd, National Cancer Institute
|
|
| 3:25 PM |
Impact of Variability in Progression Assessments on Type I and Type II Errors — Kun He, FDA; Rajeshwari Sridhara, FDA; Shenghui Tang, FDA; Xiaoping Jiang, FDA
|
|
| 3:45 PM | Floor Discussion | |
|
JSM 2009
For information, contact jsm@amstat.org
or phone (888) 231-3473. If you have questions about the Continuing Education program,
please contact the Education Department. |